🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

951 results for “Eli” Clear

  1. Selinexor

    Karyopharm Therapeutics Inc

    Acute Myeloid Leukemia (Relapsed/Refractory)

    phase 2 small molecule completed

    1 trial

  2. Selinexor

    Karyopharm Therapeutics Inc

    Acute Myeloid Leukemia (AML)

    phase 2 small molecule completed

    3 trials

  3. Selinexor

    Karyopharm Therapeutics Inc

    Acute Myeloid Leukemia

    phase 2 small molecule completed

    1 trial

  4. Selinexor

    Karyopharm Therapeutics Inc

    Thymoma

    phase 2 small molecule active

    1 trial

  5. Selinexor

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia (Relapsed/Refractory)

    phase 2 small molecule active

    1 trial

  6. Selinexor (KPT-330)

    Karyopharm Therapeutics Inc

    Squamous Cell Carcinoma

    phase 2 small molecule terminated

    1 trial

  7. Selinexor 100 mg

    Karyopharm Therapeutics Inc

    Non-Small Cell Lung Carcinoma (NSCLC)

    phase 2 small molecule completed

    1 trial

  8. Selinexor 20 MG Oral Tablet

    Karyopharm Therapeutics Inc

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

  9. Selinexor 60 MG

    Karyopharm Therapeutics Inc

    Multiple Myeloma

    phase 2 small molecule on hold

    1 trial

  10. Selinexor 60 mg

    Karyopharm Therapeutics Inc

    Myelofibrosis

    phase 2 small molecule active

    1 trial

  11. Selpercatinib

    Eli Lilly and Company

    Medullary Thyroid Cancer

    phase 2 small molecule active

    1 trial

  12. Single-dose regimen of high dosage investigational sIPV

    Sinovac Research and Development Co.,

    Poliomyelitis

    phase 2 mab completed

    1 trial

  13. Sirolimus

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hemangioendothelioma

    phase 2 small molecule active

    1 trial

  14. Sirolimus

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Kaposiform Hemangioendothelioma

    phase 2 small molecule active

    1 trial

  15. Sitravatinib, Tislelizumab, Sitravatinib

    Disc Medicine

    Uveal melanoma

    phase 2 small molecule active

    1 trial

  16. Soquelitinib

    Corvus Pharmaceuticals

    Atopic Dermatitis

    phase 2 small molecule active

    2 trials

  17. Standard drug counseling

    BRIGHT MINDS BIOSCIENCES INC.

    Opiate Dependence

    phase 2 other completed

    1 trial

  18. Standard intervention (counseling + self-help written materials)

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use

    phase 2 other completed

    1 trial

  19. Study evaluating the efficacy of the treatment after targeting PD-L1 and TIGIT in tumors with tertiary lymphoid structures

    The George Institute

    Adult patients with a histologically confirmed TLS-positive advanced or metastatic NSCLC naïve from systemic treatment or previously treated with chemotherapy and PD1/PDL1 antagonist, and not having previously been treated with CD137 agonists or investigational immune checkpoint blockade therapies, including (but not limited) anti-TIGIT, anti-LAG3. Patients must have adequate organ function with a performance status (WHO 0-1; ECOG 0-1). Patients must not have active or history of autoimmune disease or immune deficiency. The pregnant or breastfeeding women will be excluded. Other eligibility criteria are described in the related section of the protocol.

    phase 2 other active

    1 trial

  20. TACE with adebrelimab and bevacizumab

    The First People's Hospital of Lianyungang

    Adebrelimab

    phase 2 small molecule active

    1 trial

  21. TAK-062

    Takeda

    Celiac Disease

    phase 2 small molecule completed

    1 trial

  22. TAK-411

    Takeda

    Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

    phase 2 mab active

    1 trial

  23. TAXOTERE 20 mg/1 ml concentrate for solution for infusion, Budigalimab, Livmoniplimab, Paclitaxel 6 mg/mL concentrate for solution for infusion, Gemcitabine 38 mg/mL concentrate for solution for infusion

    AbbVie Deutschland GmbH & Co. KG

    Urothelial Carcinoma, Metastatic Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  24. TEMOZOLOMIDE

    Istituto Gentili S.r.l.

    Patients with well differentiated neuroendocrine neoplasia (NENs) not eligible for active antitumoral treatments due to their clinical conditions.

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources